Middle east respiratory syndrome coronavirus (mers-cov): Infection, immunological response, and vaccine development

Journal of Immunology Research

Volumn 2019, Issue , 2019, Pages

  Mubarak, Ayman ^a   Alturaiki, Wael ^b   Hemida, Maged Gomaa ^c,d  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b MAJMAAH UNIVERSITY   (Saudi Arabia)

^c KING FAISAL UNIVERSITY   (Saudi Arabia)

^d KAFRELSHEIKH UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; ANTIVIRUS AGENT; DIPEPTIDYL PEPTIDASE IV; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS RECEPTOR;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; HUMAN; INNATE IMMUNITY; MIDDLE EAST RESPIRATORY SYNDROME; NONHUMAN; REVIEW; ANIMAL; CORONAVIRUS INFECTION; IMMUNOLOGY; METABOLISM; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; DIPEPTIDYL PEPTIDASE 4; HUMANS; IMMUNITY, INNATE; MICE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RECEPTORS, VIRUS; VIRAL VACCINES;

EID: 85066865382     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2019/6491738     Document Type: Review

References (102)

1. D. Butler, "Clusters of coronavirus cases put scientists on alert, " Nature, vol. 492, no. 7428, pp. 166-167, 2012.
2. World Health Organization, Countries Agree Next Steps to Combat Global Health Threat by MERS-CoV, WHO, 2019.
3. J. F. W. Chan, S. K. P. Lau, K. K. W. To, V. C. C. Cheng, P. C. Y. Woo, and K. Y. Yuen, "Middle East respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing SARS-like disease, " Clinical Microbiology Reviews, vol. 28, no. 2, pp. 465-522, 2015.
4. A. M. Zaki, S. van Boheemen, T. M. Bestebroer, A. D. M. E. Osterhaus, and R. A. M. Fouchier, "Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia, " The New England Journal of Medicine, vol. 367, no. 19, pp. 1814-1820, 2012.
5. I. Eckerle, V. M. Corman, M. A. Muller, M. Lenk, R. G. Ulrich, and C. Drosten, "Replicative capacity of MERS coronavirus in livestock cell lines, " Emerging Infectious Diseases, vol. 20, no. 2, pp. 276-279, 2014.
6. Z. A. Memish, N. Mishra, K. J. Olival et al., "Middle East respiratory syndrome coronavirus in bats, Saudi Arabia, " Emerging Infectious Diseases, vol. 19, no. 11, pp. 1819-1823, 2013.
7. A. Assiri, G. R. Abedi, A. A. B. Saeed et al., "Multifacility outbreak of Middle East respiratory syndrome in Taif, Saudi Arabia, " Emerging Infectious Diseases, vol. 22, no. 1, pp. 32-40, 2016.
8. A. J. Alsahafi and A. C. Cheng, "The epidemiology of Middle East respiratory syndrome coronavirus in the Kingdom of Saudi Arabia, 2012-2015, " International Journal of Infectious Diseases, vol. 45, pp. 1-4, 2016.
9. R. Breban, J. Riou, and A. Fontanet, "Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk, " The Lancet, vol. 382, no. 9893, pp. 694-699, 2013.
10. M. Cotten, S. J. Watson, P. Kellam et al., "Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: A descriptive genomic study, " The Lancet, vol. 382, no. 9909, pp. 1993-2002, 2013.
11. S. Xia, Q. Liu, Q. Wang et al., "Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein, " Virus Research, vol. 194, pp. 200-210, 2014.
12. G. Lu, Y. Hu, Q. Wang et al., "Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26, " Nature, vol. 500, no. 7461, pp. 227-231, 2013.
13. A. A. Al-Qahtani, K. Lyroni, M. Aznaourova et al., "Middle east respiratory syndrome corona virus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARγ, " Oncotarget, vol. 8, no. 6, pp. 9053-9066, 2017.
14. H. J. Crespo, J. T. Y. Lau, and P. A. Videira, "Dendritic cells: A spot on sialic acid, " Frontiers in Immunology, vol. 4, pp. 491-491, 2013.
15. S. Balachandran, P. C. Roberts, L. E. Brown et al., "Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection, " Immunity, vol. 13, no. 1, pp. 129-141, 2000.
16. H. Kato, K. Takahasi, and T. Fujita, "RIG-I-like receptors: cytoplasmic sensors for non-self RNA, " Immunological Reviews, vol. 243, no. 1, pp. 91-98, 2011.
17. M. A. Anwar, S. Basith, and S. Choi, "Negative regulatory approaches to the attenuation of Toll-like receptor signaling, " Experimental & Molecular Medicine, vol. 45, no. 2, article e11, 2013.
18. J. Krishnan, K. Selvarajoo, M. Tsuchiya, G. Lee, and S. Choi, "Toll-like receptor signal transduction, " Experimental & Molecular Medicine, vol. 39, no. 4, pp. 421-438, 2007.
19. H. Kumar, T. Kawai, and S. Akira, "Toll-like receptors and innate immunity, " Biochemical and Biophysical Research Communications, vol. 388, no. 4, pp. 621-625, 2009.
20. K. Honda and T. Taniguchi, "IRFs: master regulators of signalling by Toll-like receptors and cytosolic patternrecognition receptors, " Nature Reviews. Immunology, vol. 6, no. 9, pp. 644-658, 2006.
21. J. Brown, H. Wang, G. N. Hajishengallis, and M. Martin, "TLR-signaling networks: An integration of adaptor molecules, kinases, and cross-Talk, " Journal of Dental Research, vol. 90, no. 4, pp. 417-427, 2011.
22. L. A. J. O'Neill and A. G. Bowie, "The family of five: TIRdomain-containing adaptors in Toll-like receptor signalling, " Nature Reviews Immunology, vol. 7, no. 5, pp. 353-364, 2007.
23. A. L. Totura, A. Whitmore, S. Agnihothram et al., "Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection, " mBio, vol. 6, no. 3, article e00638, 2015.
24. T. Sheahan, T. E. Morrison, W. Funkhouser et al., "MyD88 is required for protection from lethal infection with a mouseadapted SARS-CoV, " PLoS Pathogens, vol. 4, no. 12, article e1000240, 2008.
25. M. Yoneyama, M. Kikuchi, T. Natsukawa et al., "The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses, " Nature Immunology, vol. 5, no. 7, pp. 730-737, 2004.
26. R. M. Welsh and S. N. Waggoner, "NK cells controlling virusspecific T cells: rheostats for acute vs. persistent infections, " Virology, vol. 435, no. 1, pp. 37-45, 2013.
27. T. Taniguchi and A. Takaoka, "A weak signal for strong responses: interferon-Alpha/beta revisited, " Nature Reviews Molecular Cell Biology, vol. 2, no. 5, pp. 378-386, 2001.
28. J. Zhou, H. Chu, C. Li et al., "Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis, " The Journal of Infectious Diseases, vol. 209, no. 9, pp. 1331-1342, 2014.
29. H. Chu, J. Zhou, B. Ho-Yin Wong et al., "Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response, " Virology, vol. 454-455, pp. 197-205, 2014.
30. R. W. Y. Chan, M. C. W. Chan, S. Agnihothram et al., "Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures, " Journal of Virology, vol. 87, no. 12, pp. 6604-6614, 2013.
31. F. Zielecki, M. Weber, M. Eickmann et al., "Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus, " Journal of Virology, vol. 87, no. 9, pp. 5300-5304, 2013.
32. J. Canton, A. R. Fehr, R. Fernandez-Delgado et al., "MERSCoV 4b protein interferes with the NF-KB-dependent innate immune response during infection, " PLoS Pathogens, vol. 14, no. 1, p. e1006838, 2018.
33. A. H. de Wilde, V. S. Raj, D. Oudshoorn et al., "MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment, " The Journal of General Virology, vol. 94, Part 8, pp. 1749-1760, 2013.
34. B. J. Hart, J. Dyall, E. Postnikova et al., "Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays, " The Journal of General Virology, vol. 95, Part 3, pp. 571-577, 2014.
35. Q. Pan, P. E. de Ruiter, H. J. Metselaar et al., "Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C virus infection in vitro and in vivo, " Hepatology, vol. 55, no. 6, pp. 1673-1683, 2012.
36. J. M. Nicholls, L. L. M. Poon, K. C. Lee et al., "Lung pathology of fatal severe acute respiratory syndrome, " The Lancet, vol. 361, no. 9371, pp. 1773-1778, 2003.
37. E. Faure, J. Poissy, A. Goffard et al., "Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?, " PLoS One, vol. 9, no. 2, article e88716, 2014.
38. J. Zhou, H. Chu, J. F.-W. Chan, and K.-Y. Yuen, "Middle East respiratory syndrome coronavirus infection: virus-host cell interactions and implications on pathogenesis, " Virology Journal, vol. 12, no. 1, pp. 218-218, 2015.
39. W. H. Mahallawi, O. F. Khabour, Q. Zhang, H. M. Makhdoum, and B. A. Suliman, "MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile, " Cytokine, vol. 104, pp. 8-13, 2018.
40. M. J. Cameron, L. Ran, L. Xu et al., "Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome, " Journal of Virology, vol. 81, no. 16, pp. 8692-8706, 2007.
41. L. Dumoutier and J. C. Renauld, "Viral and cellular interleukin-10 (IL-10)-related cytokines: from structures to functions, " European Cytokine Network, vol. 13, no. 1, pp. 5-15, 2002.
42. R. Sabat, "IL-10 family of cytokines, " Cytokine & Growth Factor Reviews, vol. 21, no. 5, pp. 315-324, 2010.
43. S. D. Blackburn and E. J. Wherry, "IL-10, T cell exhaustion and viral persistence, " Trends in Microbiology, vol. 15, no. 4, pp. 143-146, 2007.
44. X. Xu and X. Gao, "Immunological responses against SARScoronavirus infection in humans, " Cellular & Molecular Immunology, vol. 1, no. 2, pp. 119-122, 2004.
45. J. Zhao, K. Li, C. Wohlford-Lenane et al., "Rapid generation of a mouse model for Middle East respiratory syndrome, " Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 13, pp. 4970-4975, 2014.
46. Z. Y. Yang, W. P. Kong, Y. Huang et al., "A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice, " Nature, vol. 428, no. 6982, pp. 561-564, 2004.
47. R. Channappanavar, J. Zhao, and S. Perlman, "T cellmediated immune response to respiratory coronaviruses, " Immunologic Research, vol. 59, no. 1-3, pp. 118-128, 2014.
48. L. Josset, V. D. Menachery, L. E. Gralinski et al., "Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus, " MBio, vol. 4, no. 3, 2013.
49. T. Ying, W. Li, and D. S. Dimitrov, "Discovery of T-cell infection and apoptosis by Middle East respiratory syndrome coronavirus, " The Journal of Infectious Diseases, vol. 213, no. 6, pp. 877-879, 2016.
50. H. Chu, J. Zhou, B. H. Y. Wong et al., "Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways, " The Journal of Infectious Diseases, vol. 213, no. 6, pp. 904-914, 2016.
51. T. Ishii, K. Ohnuma, A. Murakami et al., "CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 21, pp. 12138-12143, 2001.
52. M. L. Manni, K. M. Robinson, and J. F. Alcorn, "A tale of two cytokines: IL-17 and IL-22 in asthma and infection, " Expert Review of Respiratory Medicine, vol. 8, no. 1, pp. 25-42, 2013.
53. W. Jin and C. Dong, "IL-17 cytokines in immunity and inflammation, " Emerging Microbes & Infections, vol. 2, no. 1, pp. 1-5, 2013.
54. V. M. Corman, A. M. Albarrak, A. S. Omrani et al., "Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection, " Clinical Infectious Diseases, vol. 62, no. 4, pp. 477-483, 2016.
55. W. B. Park, R. A. P. M. Perera, P. G. Choe et al., "Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea, " Emerging Infectious Diseases, vol. 21, no. 12, pp. 2186-2189, 2015.
56. U. Buchholz, M. A. Möller, A. Nitsche et al., "Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012, " Euro Surveillance, vol. 18, 2013.
57. A. N. Alshukairi, I. Khalid, W. A. Ahmed et al., "Antibody response and disease severity in healthcare worker MERS survivors, " Emerging Infectious Diseases, vol. 22, no. 6, 2016.
58. W. Liu, A. Fontanet, P. H. Zhang et al., "Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome, " The Journal of Infectious Diseases, vol. 193, no. 6, pp. 792-795, 2006.
59. F. Tang, Y. Quan, Z.-T. Xin et al., "Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: A six-year follow-up study, " The Journal of Immunology, vol. 186, no. 12, pp. 7264-7268, 2011.
60. C. M. Coleman, Y. V. Liu, H. Mu et al., "Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice, " Vaccine, vol. 32, no. 26, pp. 3169-3174, 2014.
61. K. H. Chan, J. F. W. Chan, H. Tse et al., "Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests, " Journal of Infection, vol. 67, no. 2, pp. 130-140, 2013.
62. L. Du, C. Ma, and S. Jiang, "Antibodies induced by receptorbinding domain in spike protein of SARS-CoV do not crossneutralize the novel human coronavirus hCoV-EMC, " The Journal of Infection, vol. 67, no. 4, pp. 348-350, 2013.
63. V. M. Corman, J. Jores, B. Meyer et al., "Antibodies against MERS coronavirus in dromedary camels, Kenya, 1992-2013, " Emerging Infectious Diseases, vol. 20, no. 8, pp. 1319-1322, 2014.
64. A. N. Alagaili, T. Briese, N. Mishra et al., "Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia, " MBio, vol. 5, no. 2, 2014.
65. Z. A. Memish, M. Cotten, B. Meyer et al., "Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013, " Emerging Infectious Diseases, vol. 20, no. 6, pp. 1012-1015, 2014.
66. D. C. Payne, I. Iblan, B. Rha et al., "Persistence of antibodies against Middle East respiratory syndrome coronavirus, " Emerging Infectious Diseases, vol. 22, no. 10, pp. 1824-1826, 2016.
67. B. Meyer, J. Juhasz, R. Barua et al., "Time course of MERS-CoV infection and immunity in dromedary camels, " Emerging Infectious Diseases, vol. 22, no. 12, pp. 2171-2173, 2016.
68. R. Kamber, Z. Farah, P. Rusch, and M. Hassig, "Studies on the supply of immunoglobulin G to newborn camel calves (Camelus dromedarius), " The Journal of Dairy Research, vol. 68, no. 1, pp. 1-7, 2001.
69. F. Song, R. Fux, L. B. Provacia et al., "Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies, " Journal of Virology, vol. 87, no. 21, pp. 11950-11954, 2013.
70. A. Volz, A. Kupke, F. Song et al., "Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein, " Journal of Virology, vol. 89, no. 16, pp. 8651-8656, 2015.
71. L. Du, Z. Kou, C. Ma et al., "A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines, " PLoS One, vol. 8, no. 12, article e81587, 2013.
72. N. Takasuka, H. Fujii, Y. Takahashi et al., "A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice, " International Immunology, vol. 16, no. 10, pp. 1423-1430, 2004.
73. N. Zhang, S. Jiang, and L. Du, "Current advancements and potential strategies in the development of MERS-CoV vaccines, " Expert Review of Vaccines, vol. 13, no. 6, pp. 761-774, 2014.
74. H. Bisht, A. Roberts, L. Vogel et al., "Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 17, pp. 6641-6646, 2004.
75. Z. Chen, L. Zhang, C. Qin et al., "Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region, " Journal of Virology, vol. 79, no. 5, pp. 2678-2688, 2005.
76. J. H. C. M. Kreijtz, M. Goeijenbier, F. M. Moesker et al., "Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: A randomised, double-blind phase 1/2a clinical trial, " The Lancet Infectious Diseases, vol. 14, no. 12, pp. 1196-1207, 2014.
77. A. F. Altenburg, J. H. C. M. Kreijtz, R. D. De Vries et al., "Modified vaccinia virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases, " Viruses, vol. 6, no. 7, pp. 2735-2761, 2014.
78. X. Guo, Y. Deng, H. Chen et al., "Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus, " Immunology, vol. 145, no. 4, pp. 476-484, 2015.
79. W. Gao, A. Tamin, A. Soloff et al., "Effects of a SARSassociated coronavirus vaccine in monkeys, " The Lancet, vol. 362, no. 9399, pp. 1895-1896, 2003.
80. L. Du, G. Zhao, Y. Lin et al., "Intranasal vaccination of recombinant adeno-Associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-Term protection against SARSCoV infection, " Journal of Immunology, vol. 180, no. 2, pp. 948-956, 2008.
81. S. L. Pichla-Gollon, S. W. Lin, S. E. Hensley et al., "Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo, " Journal of Virology, vol. 83, no. 11, pp. 5567-5573, 2009.
82. H. Weingartl, M. Czub, S. Czub et al., "Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets, " Journal of Virology, vol. 78, no. 22, pp. 12672-12676, 2004.
83. L. Du, Y. He, Y. Zhou, S. Liu, B. J. Zheng, and S. Jiang, "The spike protein of SARS-CoV-A target for vaccine and therapeutic development, " Nature Reviews. Microbiology, vol. 7, no. 3, pp. 226-236, 2009.
84. Y. He, H. Lu, P. Siddiqui, Y. Zhou, and S. Jiang, "Receptorbinding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformationdependent epitopes that induce highly potent neutralizing antibodies, " Journal of Immunology, vol. 174, no. 8, pp. 4908-4915, 2005.
85. L. Du, G. Zhao, Y. He et al., "Receptor-binding domain of SARS-CoV spike protein induces long-Term protective immunity in an animal model, " Vaccine, vol. 25, no. 15, pp. 2832-2838, 2007.
86. J. Tang, N. Zhang, X. Tao et al., "Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus, " Human Vaccines & Immunotherapeutics, vol. 11, no. 5, pp. 1244-1250, 2015.
87. C. Ma, L. Wang, X. Tao et al., "Searching for an ideal vaccine candidate among different MERS coronavirus receptorbinding fragments-The importance of immunofocusing in subunit vaccine design, " Vaccine, vol. 32, no. 46, pp. 6170-6176, 2014.
88. L. Du, G. Zhao, Z. Kou et al., "Identification of a receptorbinding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development, " Journal of Virology, vol. 87, no. 17, pp. 9939-9942, 2013.
89. H. Mou, V. S. Raj, F. J. M. van Kuppeveld, P. J. M. Rottier, B. L. Haagmans, and B. J. Bosch, "The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies, " Journal of Virology, vol. 87, no. 16, pp. 9379-9383, 2013.
90. K. E. Pascal, C. M. Coleman, A. O. Mujica et al., "Pre-And postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection, " Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 28, pp. 8738-8743, 2015.
91. A. S. Agrawal, T. Garron, X. Tao et al., "Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease, " Journal of Virology, vol. 89, no. 7, pp. 3659-3670, 2015.
92. F. Y. Liew, S. M. Russell, G. Appleyard, C. M. Brand, and J. Beale, "Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity, " European Journal of Immunology, vol. 14, no. 4, pp. 350-356, 1984.
93. N. Zhang, J. Tang, L. Lu, S. Jiang, and L. Du, "Receptor-binding domain-based subunit vaccines against MERS-CoV, " Virus Research, vol. 202, pp. 151-159, 2015.
94. C. Ma, Y. Li, L. Wang et al., "Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines, " Vaccine, vol. 32, no. 18, pp. 2100-2108, 2014.
95. A. Podda and G. Del Giudice, "MF59-Adjuvanted vaccines: increased immunogenicity with an optimal safety profile, " Expert Review of Vaccines, vol. 2, no. 2, pp. 197-204, 2003.
96. S. Jiang, M. E. Bottazzi, L. Du et al., "Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome, " Expert Review of Vaccines, vol. 11, no. 12, pp. 1405-1413, 2012.
97. Y. V. Liu, M. J. Massare, D. L. Barnard et al., "Chimeric severe acute respiratory syndrome coronavirus (SARSCoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV, " Vaccine, vol. 29, no. 38, pp. 6606-6613, 2011.
98. K. Lovgren Bengtsson, B. Morein, and A. D. Osterhaus, "ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation, " Expert Review of Vaccines, vol. 10, no. 4, pp. 401-403, 2011.
99. R. J. Cox, G. Pedersen, A. S. Madhun et al., "Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial, " Vaccine, vol. 29, no. 45, pp. 8049-8059, 2011.
100. Y. Yang, L. Zhang, H. Geng et al., "The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists, " Protein & Cell, vol. 4, no. 12, pp. 951-961, 2013.
101. K. L. Siu, M. L. Yeung, K. H. Kok et al., "Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response, " Journal of Virology, vol. 88, no. 9, pp. 4866-4876, 2014.
102. D. Niemeyer, T. Zillinger, D. Muth et al., "Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist, " Journal of Virology, vol. 87, no. 22, pp. 12489-12495, 2013.